gene expression assays to identify patients with breast cancer for neoadjuvant treatment
Published 2 years ago • 525 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
0:55
the clinical impact of gene expression assays on early luminal breast cancer
-
6:23
stratifying patients with breast cancer by a 7-gene assay for endocrine therapy
-
5:54
roxane: impact of 21-gene assay on treatment for early breast cancer
-
2:09
hrd, rb-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in hr /her2- early bc
-
5:34
tailorx: phase 3 trial validating a 21-gene expression assay in breast cancer
-
0:40
assessing the role of 21-gene assays in breast cancer
-
0:26
identifying the need for neoadjuvant chemotherapy in stage i breast cancer
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
5:24
oncotype dx – do i need a breast cancer gene-expression assay?
-
5:15
decode heterogeneity with the breast cancer 360 panel
-
2:51
personalized ctdna during neoadjuvant therapy in pts with early-stage breast cancer
-
1:58
validation of polar, a 16-gene molecular signature, for breast conserving surgery /- radiotherapy
-
4:11
the latest in neo-adjuvant therapy for luminal breast cancer
-
53:00
genomic biomarker for predicting response in early breast cancer patients
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
2:48
using biomarkers to identify bladder cancer patients for neoadjuvant therapy
-
0:29
the role of immune biomarkers in guiding breast cancer treatment decisions
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
2:46
genetic profiling identifies patients with bc who can safely omit rt after breast-conserving surgery